Literature DB >> 15390279

Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.

Claudio Sandoval1, Sharon R Pine, Qianxu Guo, Sudha Sastry, Julian Stewart, David Kronn, Somasundaram Jayabose.   

Abstract

Infants with constitutional trisomy 21 are at increased risk of developing transient and acute megakaryoblastic leukemia (AMKL). Mutations in GATA1 have been identified in trisomy 21 patients with AMKL, and this lesion is thought to be an initial event by virtue of its presence during transient leukemia. Transient leukemia is also observed in phenotypically normal infants albeit much less commonly so. Almost all these infants are mosaic for trisomy 21, and the clinical course of transient leukemia recapitulates that observed in constitutional trisomy 21. We report a phenotypically normal infant with tetrasomy 21 transient leukemia, GATA1 mutation within exon 2, and trisomy 21 mosaicism restricted to the hematopoietic tissue. Two years after diagnosis, low levels of trisomy 21 persisted in the peripheral blood, which resolved 2.5 years after diagnosis. The GATA1 mutation was not detected at last follow-up. The literature review identified 32 phenotypically normal infants with transient leukemia. Ninety-one percent (29 of 32) were observed and three received chemotherapy at diagnosis of transient leukemia. Nineteen percent (6 of 32) developed acute leukemia, and four continued in remission (two died). Transient leukemia in trisomy 21 mosaicism recapitulates the condition observed in constitutional trisomy 21 at the biological and clinical levels. Infants should be followed for the development of acute leukemia. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15390279     DOI: 10.1002/pbc.20161

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  Transient abnormal myelopoiesis in a cytogenetically normal neonate.

Authors:  Kentaro Yanase; Keisuke Kato; Nobuko Katayama; Yoko Mouri; Chie Kobayashi; Junko Shiono; Masakazu Abe; Ai Yoshimi; Kazutoshi Koike; Jun-Ichi Arai; Masahiro Tsuchida
Journal:  Int J Hematol       Date:  2010-09-23       Impact factor: 2.490

Review 2.  Acute megakaryoblastic leukemia with acquired trisomy 21 and GATA1 mutations in phenotypically normal children.

Authors:  Rintaro Ono; Daisuke Hasegawa; Shinsuke Hirabayashi; Takahiro Kamiya; Kenichi Yoshida; Satoko Yonekawa; Chitose Ogawa; Ryota Hosoya; Tsutomu Toki; Kiminori Terui; Etsuro Ito; Atsushi Manabe
Journal:  Eur J Pediatr       Date:  2014-09-30       Impact factor: 3.183

3.  Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.

Authors:  Kazuko Kudo; Asahito Hama; Seiji Kojima; Ruriko Ishii; Akira Morimoto; Fumio Bessho; Shosuke Sunami; Naoyuki Kobayashi; Akitoshi Kinoshita; Yuri Okimoto; Akio Tawa; Ichiro Tsukimoto
Journal:  Int J Hematol       Date:  2010-03-18       Impact factor: 2.490

4.  A novel mutation in the GATA1 gene associated with acute megakaryoblastic leukemia in a Korean Down syndrome patient.

Authors:  In-Suk Kim; Eun Sil Park; Jae Young Lim; Chang-Seok Ki; Hyun Sook Chi
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.